Literature DB >> 3885106

Treatment of premature labor in insulin-dependent diabetic women.

M Miodovnik, N Peros, J C Holroyde, T A Siddiqi.   

Abstract

This retrospective study was designed to analyze the safety and efficacy of beta-sympathomimetic agents used to treat premature labor in insulin-dependent diabetic women. The study evaluated 12 insulin-dependent diabetic women who experienced 15 pregnancies complicated by premature labor. A group of 30 insulin-dependent diabetic women who delivered at term served as matched controls. Treatment consisted of parenteral and oral administration of beta-sympathomimetic drugs (ritodrine and isoxsuprine). Premature labor was diagnosed, and tocolytic treatment was initiated at a mean gestational age of 31.5 +/- 0.9 weeks. The mean gestational age at the time of delivery was 35.8 +/- 0.5 weeks. Delivery was delayed in the study group by a mean of 30.5 +/- 6.6 days. No fetal or infant deaths occurred in the study group, and there was no difference between the two groups in the incidence of neonatal morbidity. No maternal complications occurred. There were no significant differences in hemoglobin A1 levels between the two groups at any period of gestation. Thus, beta-sympathomimetic drugs may be used safely to treat premature labor in patients with insulin-dependent diabetes, provided they are administered under strictly controlled clinical settings.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3885106

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Neurological complications associated with parenteral treatment: central pontine myelinolysis and Wernicke's encephalopathy.

Authors:  P D Thompson; R F Gledhill; N P Quinn; M N Rossor; P Stanley; E N Coomes
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-08

Review 2.  Diabetes mellitus in pregnancy. What are the best treatment options?

Authors:  E A Reece; C J Homko
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.